Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether a combination of Sunitinib, Temozolomide
and Radiation Therapy would be effective in the treatment of newly diagnosed Glioblastoma
patients harboring tumors with unmethylated MGMT promoter.
Phase:
Phase 2
Details
Lead Sponsor:
Bassam Abdulkarim
Collaborators:
Canadian Cancer Society (CCS) Canadian Cancer Society Research Institute (CCSRI) Pfizer